After flexing its antibody-drug conjugate bona fides at last year’s American Society of Clinical Oncology (ASCO) conference, ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

For investors in gene therapy biotech bluebird bio, a wait-and-see approach toward a proposed acquisition has paid off. | For ...

Add Sanofi to the list of drugmakers committing billions to bolster their operations in the United States as President Donald ...

Despite holding the lead with its complement inhibitor Syfovre, Apellis Pharmaceuticals is discovering that the geographic ...

Workers at AbbVie’s manufacturing facility in Carrigtwohill, Ireland—one of six plants the Illinois drugmaker runs in the ...

Famar, a portfolio company of the private equity firm of MidEuropa, is set to acquire a sterile manufacturing facility in ...

A new promo for Roche’s blockbuster hemophilia A drug Hemlibra focuses less on those with the genetic bleeding disorder and ...

With massive social media hype around its intricate world-building and steamy love scenes, perhaps no literary genre has made ...

Mayne Pharma is in trouble with the FDA. The agency accused Mayne of giving a misleading impression of the risks of its oral ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...

About a month after disclosing a $50 billion investment in its U.S. | Roche has earmarked more than $700 million to construct ...